{"entity":{"id":"nct06959550","kind":"trial","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of ivonescimab in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.","summary":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06959550 by M.D. Anderson Cancer Center, with a registry enrolment figure of 90 participants, started 2025-07-28 and due to reach its primary completion in 2028-07-01. Interventions recorded: Ivonescimab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: 1. Safety and Adverse Events (AEs). Colorectal eligibility wording from the registry: \"Histological or cytological confirmed advanced, metastatic adenocarcinoma of colon or rectum\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06959550","url":"https://clinicaltrials.gov/study/NCT06959550"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["ivonescimab"],"companies":["summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06959550","phase":"2","setting":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","sponsor":"M.D. Anderson Cancer Center","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06959550/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}